home > Program


Sicentific Program(Day 1/Day 2)

연수평점 : 최대 8점(2일간)

Time Program Speaker
08:30-09:00 Registration
09:00-10:30 KPS-APSU Meeting
10:30-10:50 Coffee Break
10:50-12:00 Poster Session
12:00-13:00 Lunch
13:00-13:20 Opening Ceremony Jun Hyuk HONG (President of KPS)
Ji Youl LEE (President of APSU)
13:20-14:30 Session I: Kidney Cancer I Seong Il SEO (Korea),
Lukman HAKIM (Indonesia)
15 Active surveillance and ablative therapies : When and how Taekmin KWON (KOREA)
20 Single port prostatectomy: Simple, retropubic and retzius sparing, The Mayo Clinic Experience Matthew K. TOLLEFSON (USA)
20 The evolving role of cytoreductive nephrectomy after Carmena Surena F. MATIN (USA)
15 Panel Discussion : JinKyu OH(Korea), Edmund CHIONG (Singapore), Norio NOMOMURA (Japan), Todd M. MORGAN (USA), Gyeong Eun MIN (Korean), Bum Sik TAE(Korea)
14:30-15:35 Session II: Bladder Cancer I Tag Keun YOO (Korea)
Bannakij LOJANAPIWAT (Thailand)
15 Beyond BCG in non-muscle invasive bladder cancer Hyung Suk KIM (Korea)
15 Update of lymph node dissection during radical cystectomy Wan SONG (Korea)
20 Comparative Efficacy of Robotic Assisted Radical Cystectomy Michael S. COOKSON (USA)
15 Panel Discussion : Jun Hyun HAN (Korea), Jin Seon CHO (Korea), Byung Hoon KIM(Korea), In-Chang CHO (Korea), Seol Ho CHOO (Korea), Seung Chol PARK (Korea), Jung Sik HUH (Korea)
15:35-15:50 Coffee Break
15:50-17:00 Session III: Prostate Cancer I Ji Youl LEE (Korea)
Rainy UMBAS (Indonesia)
15 The role of MRI before prostate biopsy Myungsun SHIM (Korea)
20 PSMA PET is changing the landscape of prostate cancer Timothy F. DONAHUE (USA)
20 The implications of germline testing in localized prostate cancer Todd M. MORGAN (USA)
10 Panel Discussion :Taek Won KANG (Korea), Edmund CHIONG (Singapore), Teng Aik ONG (Malaysia), Hong Seok PARK (Korea), Young Eun YOON (Korea), Young Hwii KO (Korea)
17:00- Welcome Dinner
Time Program Speaker
08:30-08:50 Registration
08:50-09:00 Welcome Message Kyu-Sung LEE (President of KUA)
09:00-10:00 Session IV: Potpourri: Issues to Consider Kyung Seop LEE (Korea)
Edmund CHIONG (Singapore)
15 Efficacy and Safety of Tamsulosin 0.4mg in Patients with LUTS/BPH Se Yun KWON (Korea)
15 GnRH agonist in prostate cancer Se Young CHOI (Korea)
15 Optimal management of male LUTS/BPH – Combination therapy of tamsulosin & dutasteride Byung Ha CHUNG (Korea)
15 Panel Discussion : Jeong Seok HWA (Korea), Seung-Ju LEE (Korea), Tae Young JUNG (Korea), Jae Young PARK (Korea), Phil Hyun SONG (Korea), Lukman HAKIM (Indonesia)
10:00-10:20 Coffee Break
10:20-11:50 Session V: Prostate Cancer II Norio NONOMURA (Japan)
Hyun Moo LEE (Korea)
20 Focal therapy is not yet ready for prime time Timothy F. DONAHUE (USA)
20 Single port prostatectomy: Simple, retropubic and retzius sparing, The Mayo Clinic Experience Matthew K. TOLLEFSON USA)
15 Artificial urinary sphincter for the management of post-prostatectomy incontinence Kwang Jin KO (Korea)
15 Treatment of Patients with Biochemical Recurrence after Radical Prostatectomy Hakmin LEE (Korea)
20 Panel Discussion : Kyung Hyun MOON (Korea), Hwang Gyun JEON (Korea), Seung Hwan LEE (Korea), Bannakij LOJANAPIWAT (Thailand), Surena F. MATIN (USA), Sun Il KIM (Korea), Seong Soo JEON (Korea)
11:50-12:50 Lunch
12:50-14:15 Session VI: Prostate Cancer III Byung Ha CHUNG (Korea)
Teng Aik ONG (Malaysia)
20 Management of Metastatic and Castration Resistant CRPC: What’s New? Michael S. COOKSON (USA)
15 Application of intensive treatment of positive pelvic lymph nodes Kwang Hyun KIM (KOREA)
15 Local treatment in de novo metastatic prostate cancer Won Sik JANG (Korea)
20 Prostate Cancer Genomics: Where Are We & Where Are We Going? Todd M. MORGAN (USA)
15 Panel Discussion : Sung Kyu HONG (Korea), Yun Beom KIM (Korea), Lukman HAKIM (Indonesia), Norio NOMOMURA (Japan), Michael S. COOKSON (USA), Junghyun KIM (Korea), Sang Hyeon CHEON (Korea)
14:15-14:40 Coffee Break
14:40-15:45 Session VII: Upper Tract Urothelial Cancer Jae IL CHUNG (Korea)
Chun Il KIM (Korea)
15 Nephron-sparing surgery of upper tract urothelial cancer Sung Yong CHO (Korea)
15 Perioperative chemotherapy for upper tract urothelial cancer Jong Chan KIM (Korea)
20 Clinical updates and translational correlates Surena F. MATIN (USA)
15 Panel Discussion : Jun Sung KOH (Korea), Moon Ki JO(Korea), Jae Heon KIM (Korea), Jae-Seung CHUNG (Korea), Ho Kyung SEO (Korea)
15:45-17:00 Session VIII: Prostate Cancer IV Sang Eun LEE (Korea)
Jun Hyuk HONG (Korea)
15 Tailoring therapy in metastatic hormone-sensitive prostate cancer Wook NAM (Korea)
15 M0CRPC : is imaging good enough? Won Ik SEO (Korea)
15 AR-targeting therapy in non-metastatic (M0) castration resistant prostate cancer Jongwook PARK (Korea)
15 Bone-targeting therapy in metastatic prostate cancer Sung Han KIM (Korea)
15 Panel Discussion : Sung-Woo PARK (Korea), U-Syn HA (Korea), Bannakij LOJANAPIWAT (Thailand), Young-Sig KIM (Korea), Jae Young JOUNG (Korea), Kyo Chul KOO (Korea)
17:00 Closing Remarks Jun Hyuk HONG (President of KPS)
Ji Youl LEE (President of APSU)